Section 7 AAC 70.125 - Additional requirements for providing opioid use disorder treatment services(a) To be approved by the department to provide opioid use disorder treatment services, a community behavioral health services provider described in 7 AAC 70.010(a)(1) or a substance use disorder treatment provider described in 7 AAC 70.010(a)(2) must (1) comply with each requirement of 42 C.F .R. Part 8, adopted by reference in 7 AAC 70.910; (2) be accredited or working toward accreditation in accordance with 7 AAC 70.150; (3) be certified under 42 C.F.R. Part 8 by the United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA); (4) be registered with the federal Drug Enforcement Administration; (5) have a valid drug room license from the Board of Pharmacy under 12 AAC 52.800(a); (6) provide a comprehensive range of medical and behavioral health clinic and rehabilitative services that address addiction and addictive behavior; (7) cooperate with the Department of Corrections to assist with opiate withdrawal or maintenance treatment of a recipient in custody; (8) cooperate with the attending physician and hospital staff to continue opioid treatment services upon hospitalization of a recipient; and (9) adhere to the Federal Guidelines for Opioid Treatment Programs, adopted by reference in 7 AAC 70.910. (b) All opioid use disorder treatment services, including behavioral health clinic and rehabilitation services, must be medically necessary and clinically appropriate in accordance with the (1)ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co- Occurring Conditions, adopted by reference in 7 AAC 70.910; (2)Diagnostic and Statistical Manual of Mental Disorders, adopted by reference in 7 AAC 70.910; and (3)International Classification of Diseases - 10th Revision, Clinical Modification (ICD-10-CM), adopted by reference in 7 AAC 70.910. (c) Unless a recipient voluntarily terminates participation in the opioid use disorder treatment program, the provider may not withdraw opioid use disorder treatment services earlier than 21 days after beginning treatment. However, the medical director may impose a withdrawal of services after fewer than 21 days, and without the recipient's voluntary termination of participation, if withdrawal of services is medically necessary for the safety and well-being of the recipient. The provider shall have written withdrawal procedures for withdrawing services from a recipient without the recipient's voluntary termination of participation. The provider shall explain those procedures to the recipient before imposing them. (d) Services must be available to assure the reasonable continuity of care of each recipient. Hours of operation must reasonably consider and accommodate recipient schedules, including schedules for transportation, school, homemaking, employment, and child care, and in reasonable consideration of the provider's operational costs. In order to meet the requirements under this subsection, a provider shall ensure that (1) services are made available at least six days a week, 52 weeks a year, with the exception of closures on state and federal holidays; a provider shall inform the department of the provider's published hours of operation, including holidays and other scheduled closures; (2) the provider offers medication dispensing Monday through Friday during a regular 9:00 a.m. - 5:00 p.m. business day; and (3) medication dispensing is scheduled for hours needed to reasonably accommodate recipient needs, including on Saturdays, on Sundays, and after the business day under (2) of this subsection if indicated by recipient needs. (e) For an emergency leading to temporary closure of an opioid use disorder treatment program, an up-to-date plan for emergency administration of medications must be maintained. The plan must (1) provide for the capability to respond to emergencies on a 24-hour basis; and(2) identify an alternative dosing location that (A) is secured in advance; and (B) complies with registration requirements of the federal Drug Enforcement Administration. (f) In this section, "medical director" has the meaning given in 42 C.F.R. 8.2, adopted by Eff. 4/9/2017, Register 222, July 2017; am 4/24/2020, Register 234, April 2020Authority:AS 47.05.010
AS 47.30.470
AS 47.30.475
AS 47.30.477
AS 47.30.530
AS 47.30.540
AS 47.30.570
AS 47.37.140